Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $226.10 | Total: $1,130.50 |
| 1 | 10 | $191.52 | Total: $1,915.20 |
| 1 | 25 | $162.26 | Total: $4,056.50 |
| 1 | 50 | $138.32 | Total: $6,916.00 |
| 1 | 100 | $119.70 | Total: $11,970.01 |
Overview
Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.
Chemical Properties
| Molecular Formula | C22H27N5O5 |
| Molecular Weight | 441.48 |
| CAS Numbers | 2079939-05-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C([C@@H](C(N[C@H](C(OC(C)C)=O)CCC(C=[N+]=[N-])=O)=O)NC(C)=O)C=1C=2C(NC1)=CC=CC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Yumi Yokoyama, et al. DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo. Cancer Res 2021;81[13_Suppl] Abstract nr 1563.